← Leaderboards
Selina Y Chen-Kiang
Weill Medical College Of Cornell Univ
$10,455,922
Attributed
$10,849,197
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$19,764,039 · 10
By mechanism
P01$11,649,105 · 3
R01$7,716,114 · 6
R21$398,820 · 1
Top collaborators
- Christopher Edward Mason2 shared
- Jihye Paik1 shared
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- Hsiou-Chi Liou$1,948,359
Others in their field
Top investigators on “Cell Cycle”
- Bruce W Stillman · Cold Spring Harbor Laboratory$87,228,479
- Gregory D Peterson · University Of Tennessee Knoxville$84,527,696
- Nevan J Krogan · University Of California, San Francisco$83,822,021
- Mary M Horowitz · Medical College Of Wisconsin$76,714,344
- Frank Patrick McCormick · University Of California San Francisco$75,259,666
- David Heimbrook · Leidos Biomedical Research, Inc.$68,555,131
Research focus
Cell CycleCyclin D1BaseCombined Modality TherapyResponseTherapeutic TargetResistanceInhibitor/AntagonistG1 ArrestDrug ResistanceCdk4 GeneTumorCell LineMantle Cell LymphomaPharmaceutical PreparationsNovel TherapeuticsEventGene ExpressionDisease ProgressionMalignant NeoplasmsCellsOverexpressionScheduleClinical Trials
Grant awards (39)
Mechanism-Based Targeting of Mantle Cell Lymphoma$1,737,096
P01 · FY2022 · CA · contact PI
Project 1: Therapeutic targeting of CDK4 in Mantle Cell Lymphoma$332,424
P01 · FY2022 · CA · contact PI
Core A: Administrative Core$194,189
P01 · FY2022 · CA · contact PI
Mechanism-Based Targeting of Mantle Cell Lymphoma$1,788,373
P01 · FY2021 · CA · contact PI
Project 1: Therapeutic targeting of CDK4 in Mantle Cell Lymphoma$344,603
P01 · FY2021 · CA · contact PI
Core A: Administrative Core$198,152
P01 · FY2021 · CA · contact PI
Mechanism-Based Targeting of Mantle Cell Lymphoma$1,807,672
P01 · FY2020 · CA · contact PI
Project 1: Therapeutic targeting of CDK4 in Mantle Cell Lymphoma$349,843
P01 · FY2020 · CA · contact PI
Core A: Administrative Core$198,152
P01 · FY2020 · CA · contact PI
Mechanism-Based Targeting of Mantle Cell Lymphoma$1,777,797
P01 · FY2019 · CA · contact PI
Project 1: Therapeutic targeting of CDK4 in Mantle Cell Lymphoma$344,395
P01 · FY2019 · CA · contact PI
Core A: Administrative Core$192,207
P01 · FY2019 · CA · contact PI
Mechanism-Based Targeting of Mantle Cell Lymphoma$1,803,904
P01 · FY2018 · CA · contact PI
Chromatin remodeling and FOXO in targeting CDK4 in mantle cell lymphoma$387,731
R01 · FY2018 · CA · contact PI
Project 1: Therapeutic targeting of CDK4 in Mantle Cell Lymphoma$377,925
P01 · FY2018 · CA · contact PI
Cell cycle reprogramming for therapeutic targeting of BTK in lymphoma$351,713
R01 · FY2018 · CA · contact PI
Core A: Administrative Core$202,373
P01 · FY2018 · CA · contact PI
Cell cycle reprogramming for therapeutic targeting of BTK in lymphoma$351,713
R01 · FY2017 · CA · contact PI
Cell cycle reprogramming for therapeutic targeting of BTK in lymphoma$351,713
R01 · FY2016 · CA · contact PI
Cell cycle reprogramming for therapeutic targeting of BTK in lymphoma$351,713
R01 · FY2015 · CA · contact PI
Cell cycle reprogramming for therapeutic targeting of BTK in lymphoma$351,713
R01 · FY2014 · CA · contact PI
Defining molecular biomarkers for CDK4/6-based cancer therapy by RNA sequencing$178,275
R21 · FY2014 · CA · contact PI
Defining molecular biomarkers for CDK4/6-based cancer therapy by RNA sequencing$220,545
R21 · FY2013 · CA · contact PI
CDK control of myeloma pathogenesis$278,662
R01 · FY2011 · CA · contact PI
CDK control of myeloma pathogenesis$287,280
R01 · FY2010 · CA · contact PI
CDK control of myeloma pathogenesis$756,831
R01 · FY2009 · CA · contact PI
CDK control of myeloma pathogenesis$287,280
R01 · FY2009 · CA · contact PI
CDK control of myeloma pathogenesis$287,280
R01 · FY2008 · CA · contact PI
CDK control of myeloma pathogenesis$287,280
R01 · FY2007 · CA · contact PI
CDK Inhibitor and B Cell Terminal Differentiation$370,344
R01 · FY2006 · AR · contact PI
CDK Inhibitor and B Cell Terminal Differentiation$379,256
R01 · FY2005 · AR
CDK Inhibitor and B Cell Terminal Differentiation$411,038
R01 · FY2004 · AR
CDK Inhibitor and B Cell Terminal Differentiation$411,038
R01 · FY2003 · AR
CELL CYCLE AND APOPTOSIS IN PLASMA CELL TUMORIGENESIS$292,526
R01 · FY2003 · CA
CDK Inhibitor and B Cell Terminal Differentiation$411,038
R01 · FY2002 · AR
CELL CYCLE AND APOPTOSIS IN PLASMA CELL TUMORIGENESIS$285,586
R01 · FY2002 · CA
CELL CYCLE AND APOPTOSIS IN PLASMA CELL TUMORIGENESIS$278,850
R01 · FY2001 · CA
MECHANISM OF CYTOKINE INDUCED B CELL DIFFERENTIATION$273,226
R01 · FY2000 · AR
CELL CYCLE AND APOPTOSIS IN PLASMA CELL TUMORIGENESIS$272,303
R01 · FY2000 · CA